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Abstract. The number of people living with HIV/AIDS in the People’s Democratic Republic of Laos (also 
known as Laos PDR) is estimated at 13,600 and the number of people in need of antiretroviral therapy at 
8,000. Today, around 3,200 HIV infected individuals receive treatment in seven centres throughout the coun-
try. Until recently, antiretroviral treated patients were followed-up only on the basis of clinical and immuno-
logical criteria.
In 2009 the Centre d’Infectiologie Christophe Mérieux in Laos PDR (CICML) signed a collaboration agree-
ment with the national Centre of HIV/AIDS/STI (CHAS) for the implementation of HIV viral load testing 
(VLT) in the country, leading to the technological transfer of the ANRS generic assay (HIV Generic charge 
virale, Biocentric, Bandol, France). The introduction of HIV VLT has been accompanied through national 
HIV workshops every 6 months. From June 2009 to December 2011, HIV viral load has been measured in 
1,782 antiretoviral-treated patients. Of these, 97% were on reverse-transcriptase inhibitor -based 1st line 
regimen. 
HIV viral load was undetectable (<250 copies/ml) for 1,491 out of 1,782 (84%) antiretroviral-treated patients. 
Four months after adherence strengthening, HIV viral load became undetectable for 179/247 patients (72.5%) 
while 68/247 patients (27.5%) remained viremic (median viral load: 4.1 Log
10
).
This report demonstrates the feasibility of setting up an affordable HIV viral load generic test at a national 
level in Laos PDR. Interestingly, only 16% of antiretroviral-treated patients presented with detectable VL at 
their irst viral load measurement. Importantly, almost two thirds of them have controlled their viral load after 
strengthening their adherence to treatment.
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1. Introduction
The Laos People’s Democratic Republic (Laos PDR) is a 
landlocked country in Southeast Asia, bordered by the 
Republic of the Union of Myanmar and the People’s Republic 
of China to the northwest, Vietnam to the east, Cambodia to 
the south and Thailand to the west.
Spread over 236,800 km2, with 6.8 million inhabitants in 
2009, the country has a population density of 28.8inhabitants 
perkm2; 69% living in rural areas and 31% in urban areas. 
Laos PDR is divided into 17 provinces further divided into 
districts and then villages. The capital city is Vientiane (350 
000 inhabitants). Other large cities include Savannakhet 
(130,000 inhabitants), Pakse (70,000 inhabitants) and 
LuangPrabang (60,000 inhabitants).
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1.1 Dynamics of HIV infection in Laos PDR
The Laos PDR is often considered as the country in the 
Greater Mekong Region with the lower HIV-prevalence in 
the general population. However, the Laos PDR is undergo-
ing rapid socioeconomic changes, leading to behaviours that 
may place some Laotians at increased risk of HIV infection. 
Because of its geographical location in the heart of the 
Mekong region, intravenous drug use, and unsafe sexual 
practices, Laos PDR is at high risk of a greater epidemic. 
Since the irst HIV case was identiied in 1990, the number of 
infections has constantly increased. Although only less than 
1% of sex workers were HIV-infected in 2000, a 2004 survey 
of the prevalence of sexually transmitted infections (STIs) 
among service women found that chlamydia /gonorrhoea 
prevalence was 45% in the capital Vientiane, 43.6% in the 
border province of Bokeo, and 27.9% in the southern prov-
ince of Champasak, indicating the vulnerability of these 
women to HIV (UNAIDS, 2010). In 2005, nearly 5% of in-
jecting drug users (IDUs) were found HIV infected and 
UNAIDS estimated that 3,700 people in Laos PDR were liv-
ing with HIV. In 2009, the estimated HIV prevalence among 
15 to 49 year old was close to 0.2% giving an estimated num-
ber of people living with HIV/AIDS (PLWHA) of 13,600, 
according to UNAIDS (2010). 
1.2 An increasing number of patients  
on antiretroviral therapy (ART)
In response to its precarious HIV situation, the Government 
of Laos PDR has provided strong political commitment to 
support a multi-sectorial response. The action of key interna-
tional and national partners has been also invaluable. 
Médecins Sans Frontières (MSF) opened its HIV/AIDS proj-
ect in Savannakhet, southern Laos PDR, in 2001. Along with 
providing urgently needed treatment, the project aimed to 
sensitize the general public and the authorities to the exis-
tence of HIV/AIDS and the need for specialized care. MSF’s 
project offered free services for patients, who until recently 
travelled from all provinces to beneit from them. In 
Savannakhet, MSF provided prophylaxis and treatment for 
opportunistic infections and ART. By 2007, HIV counselling, 
testing and ART services had been handed over to the hospi-
tal. By the end of 2007, 608 patients were receiving care and 
treatment, with 490 of them on ART. 
In spring 2005, the Ministry of Health of Laos PDR re-
quested the support of the French public interest group 
“Ensemble pour une solidarité thérapeutique hospitalière en 
réseau” (ESTHER) (“Together for a therapeutic solidarity 
network hospital”). An agreement between the two countries 
was signed in April 2007. The partnership project between 
Mahosot Hospital in Vientiane, Saint-Louis Hospital, 
Assistance Publique/ Hopitaux de Paris (APHP) in Paris, and 
Strasbourg University Hospital, along with the hospital mem-
bers of the Program for HIV Prevention and Treatment 
(PHPT) network in Chiang Mai, began in early 2008. This 
project, planned for a 5 year period (2008 - 2012), has been 
co-funded by the French Development Agency (AFD) as part 
of its health project in Laos PDR. The partnership 
project between the Luang Prabang Provincial Hospital, 
which became the 4th ART centre in the country in February 
2009, and Bichat-Claude Bernard Hospital-APHP got under-
way in March 2009. The main objective was to strengthen the 
capacities of the health care system at national level and in 
both hospitals, through mentoring, training workshops and 
exchange of practical experience. Access to viral load was 
improved through the inancing of viral load tests in Mahosot 
and Luang Prabang Hospital.
To date, seven centres have been gradually established: 
two in Vientiane (Mahosot, Setthatirath), 3 in the north 
(Luong NamTha, Bokeo, Luang Prabang) and two in the 
south (Savannakhet and Pakse) (Figure 1). At the end of 2011 
the number of patients receiving ART was estimated at 2,115. 
1.3 Lack of virological monitoring
Despite the aforementioned accomplishments, Laos PDR had 
still many challenges to address including the lack of viro-
logical monitoring to follow antiretroviral-treated (ART) pa-
tients. Indeed, before 2009, monitoring of patients on ART 
was done only on the basis of clinical and immunological 
(CD4 lymphocytes count) criteria and only very few patients 
had access to HIV viral load measurement in Thailand for 
USD 200 to 250 with results released after 4 to 8 weeks. In 
the absence of viral load measurement, the early diagnosis of 
HIV infection in newborns and children under18 months was 
impossible. 
2. HIV viral load implementation in Laos PDR
The Centre d’Infectiologie Christophe Mérieux of Laos PDR 
(CICML) was established in 2009 with a mission to serve 
public health. Today, the CICML is integrated into the Laos 
public health infrastructures and is under the guidance of the 
Laos Ministry of Health.
Within the year, the CICML signed an agreement with the 
national Centre for HIV/AIDS/STI (CHAS) for the introduc-
tion of HIV viral load testing (VLT) in the country. The 
CICML has capitalized on the expertise of IPC for the imple-
mentation of the HIV viral load using the generic test devel-
oped by the French Agence Nationale de Recherche sur le 
Sida et les hépatites virales (ANRS) (Rouet et al, 2007; Rouet 
et al, 2008) and commercialized by Biocentric, France. This 
generic test, based on real time technology, targets the long 
terminal repeat (LTR) region of HIV which allows quantiica-
tion of the vast majority of HIV-1M strains circulating around 
the world including HIV-1 non-B viruses such as the CRF01_
AE subtype circulating in South-East Asia (Menu et al, 1999; 
Nouhin et al, 2009).
This generic assay is also particularly sensitive with a limit 
of detection of 50 copies/ml using 1 ml plasma, or 250 cop-
ies/ml using 200 microlitres of plasma (Rouet et al, 2008). In 
contrast to the other commercialized tests, the Biocentric as-
say uses an open system that offers great lexibility in the 
choice of reagents, consumables and equipment required for 
both the nucleic acid extraction and the ampliication/detec-
tion steps. Based on real-time PCR, the risks of nucleic acid 
contamination are greatly reduced. Routinely used in clinical 
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trials conducted by the ANRS, in France and also in southern 
countries, such as in Cambodia and Africa (Kesho Bora Study 
Group, 2011; Blanc et al, 2011), it has been gradually imple-
mented in around 20 African and Asian countries. This ap-
proach signiicantly reduces the cost of this analysis to USD 
20 to 40 including reagents, transport, staff, and 
consumables.
In Cambodia, both HIV-RNA and HIV-DNA VL assays 
(Generic HIV charge virale and HIV DNA cell, Biocentric, 
Bandol, France) were implemented at Pasteur Institute 
Cambodia (IPC) in 2005. Between 2005 and 2011, 28,000 
HIV RNA VL have been done for 13,000 HIV patients repre-
senting one third of the ART- patients in Cambodia. During 
the same period of time, nearly 3,700 exposed infants less 
than 18 months of age have been screened for HIV infection 
by detection of HIV-RNA on whole blood or HIV-DNA on 
dried blood spot (DBS). 
2.1 The Technical transfer:
It was clear to all partners that the training of the laboratory 
staff working at the CICML should be also accompanied by 
1) providing training to clinicians on the use and interpreta-
tion of HIV viral load, 2) establishing national logistics for 
the specimen collection/transportation and data feedback to 
the sites, and 3) warranting the sustainability through ensur-
ing the funding of viral load at the national level.
The technology transfer of the viral load from IPC to 
CICML occurred between May and September 2009 during 
missions of Laos technicians to IPC and Khmer technicians 
from IPC to CICML. During these missions, intra and inter 
laboratory quality controls were established, followed-up by 
registration of CICML to international external quality con-
trols such as Quality Control for Molecular Diagnostics 
(QCMD), United Kingdom National External Quality 
Assessment Service (UKNEQAS), and now US Centre for 
Disease Control and Prevention (US CDC). 
To accompany the introduction of this analysis in Laos 
PDR, it was decided to organize semi-annual national work-
shops involving representatives of CHAS, WHO, ESTHER, 
associations of people living with HIV/AIDS, laboratory 
staff and clinicians from the seven treatment centres, and in-
vited experts in the ields of virology, antiretroviral therapy, 
and psycho-social sciences. It was decided that each work-
shop would include a session dedicated to clinical case stud-
ies. These workshops, co-organized by the CICML and IPC 
were inancially supported by the national program through 
the Global Fund, ESTHER and Fondation Mérieux.
2.2 The national workshops on HIV viral load 
2.2.1 The irst national workshop 
Between May and October 2009, a total of 144 viral loads 
were carried out. The irst national workshop on HIV Viral 
load in Laos PDR was held in Vientiane in November 2009. 
This meeting provided the opportunity to make the authori-
ties and other stakeholders aware of the availability of HIV 
VLT in Laos PDR.
It also helped to set up logistics for the transportation of 
treatment site samples to the CICML. It was decided that fro-
zen plasma specimen from the North (Bokeo, Luang Prabang 
and Luong Namtha) would be sent once a week by plane to 
Vientiane, and that plasma specimen from the south 
(Savannakhet and Pakse) would be sent to the CICML after 8 
to 11 hours by bus each week. EDTA blood specimen from 
Mahosot and Setthatirath in Vientiane would be referred at 
room temperature and on a weekly basis directly to the 
CICML.
All samples are sent anonymously with a unique patient 
code. After receipt and registration, plasma samples are 
stored at -80 °C until use. All specimens are supposed to ar-
rive at the beginning of the week. Through this method, 
CICML can run the test (extraction, ampliication/detection) 
at the end of the same week in order to release the results at 
the beginning of the following week. 
These results are sent by fax or electronically by email to 
the site managers. The original results are sent back to the 
sites by carriers or identiied couriers. Thus, the time between 
receipt of samples at CICML and receipt of the results by the 
sites should not exceed 7 to 10 days.
During the irst workshop, the funding of viral loads by the 
national program through the Global Fund was discussed in 
order to guarantee the sustainability of the action. Similarly, 
discussions started for the elaboration of national guidelines 
on virological monitoring of HIV infected subjects.
2.2.2 The second national workshop 
The second national workshop was held 6 months later in 
Vientiane in May 2010. It has been an opportunity to see, that 
despite the established procedures, the number of samples 
received at CICML was lower than expected: between the 













































































































Total number of VLT done=  3046
Figure 2. Number of HIV VL tests per months performed at 
the CICML. From June 2009 to December 2011, a total num-
ber of 3,046 tests have been done. WS1-4 means Workshop 
1- 4.
Discussions with partners have revealed that one of the 7 
centres, managing a large number of patients referred very 
few samples at the CICML. The measures put in place helped 
to correct this, and to triple the number of viral loads per-
formed between the second and the third workshop.
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2.2.3 The third national workshop
This workshop, held in Vientiane in November 2010, focused 
on HIV-drug resistance. This workshop was an opportunity to 
present the ARV resistance testing transferred from IPC to 
CICML and to emphasize the need to strengthen the patients’ 
adherence to ART and to monitor their viral load 3 months 
after a irst detectable VL, at least, before considering any 
treatment change or switching to protease inhibitor (PI)-
based second line. A special session was dedicated to the psy-
chosocial support and adherence to treatment with the partici-
pation of two experts in social sciences and representatives of 
PLWHA in Laos PDR. 
2.2.4 The fourth national workshop
This workshop was held in Luang Prabang in May 2011. As 
shown in Figure 2, a highly signiicant decrease in the num-
ber of VL done at the CICML was observed between 
November 2010 and May 2011 (417 HIV VL compared to 
735 performed during the previous period). This point was 
discussed during the 4th Workshop. In fact, the lack of fund-
ing at the national level had indeed temporarily slowed down 
the viral monitoring activity. With this problem solved, the 
CICML reached its cruising workload with an average of 200 
tests per month. The 4th workshop was also an opportunity to 
introduce the technical transfer of the early infant diagnosis 
of HIV infection on DBS from IPC to CICML and to empha-
size the need to strengthen urgently the Prevention of Mother-
to-child HIV Transmission (PMTCT) programs in the 
country.
3. Virological efficacy of antiretroviral therapy
From May 2009 to December 2011 the CICML received a 
total of 3,056 blood specimen corresponding to 1,782 pa-
tients on ART out of the 3,209 recorded in the seven treat-
ment centers. 
National treatment centres (n=7)
ART-Patients: n= 2,014
CICML 1st HIV VLT
ART-Patients: n=1,782 (88.5%)
HIV VL < 250 cp/ml
n=1,491 (84%)




Control 4 months later (2nd HIV VLT)
HIV VL < 250 cp/ml
n=179 (72.5%)
HIV VL > 250 cp/ml
n=68 (27.5%)
HIV drug resistance testing (n=50)
Figure 3. Patients and results low chart
Savannakhet and Setthatirath are the larger treatment cen-
tres with respectively 1,065 and 1,150 patients registered. As 
indicated in Figure 3, at least one VL was done for 1,782 out 
of 2,014 patients on ART (88.5%) (Paboriboune et al, 2012). 
The proportion of patients on ART who received at least one 
viral load measurement ranged from 66.3% in Luang Prabang 
to 89% in Bokeo. The median age was 35 years (range: 0.4 
– 71), 848 (47.6%) were females and 934 (52.4%) were 
males.
Among the 1,782 patients on ART with at least one VLT, 
1,734 (97%) received reverse transcriptase inhibitor (RTI)-
based 1st line regimen (mean duration on1st line: 2.7 years, 
standard deviation: 1.9) with 988 (57%) receiving d4T/3TC/
NVP, 312 (18%) AZT/3TC/NVP and 191 (11%) d4T/3TC/
EFV (other RTI-based regimen: 14%).
Nearly 3% out of 1,782 were on PI-based 2nd line regimen 
(d4T/3TC/LPV/r: 59%; 3TC/TDF/LPV/r: 21%; AZT/3TC/
LPV/r: 10%, other:  10%). The mean duration on PI-based 2nd 
line regimen was 2.9 years (standard deviation: 2.1).
As indicated in Figure 3, the irst HIV VL testing revealed 
that only 291 (16%) of 1,782 patients on ART had 
detectable viral loads (mean HIV VL: 3.5Log
10
), 7 of them 
receiving a PI-based 2nd line regimen. This means that 84% 
of ART-patients had successful virological suppression.
The adherence to treatment was strengthened by psycho-
social counselors for 247 of the 291 viremic patients followed 
by a control viral load four months later.The second HIV VL 
became undetectable for 179 (72.5%) out of 247, while 
68/247(27.5%) kept unsuppressed VL (mean HIV VL: 
4.1Log
10
) (Paboriboune et al, 2012). Drug resistance testing 
done for 50/68 showed a high level of resistance to 3TC and 
NVP/EFV, reverse transcriptase inhibitors used in the 1st line 
therapy (83-92%).
4. Discussion
We report here the successful implementation of HIV viral 
load testing at the CICML, in Vientiane, the capital city of 
Laos PDR, offering access to virological monitoring of near-
ly 90% of patients on ART, followed-up in the 7 ART centers 
of the country.
The participation of all stakeholders in the ight against 
HIV/AIDS is a key factor in this success. The feasibility and 
interest of open systems to manage HIV viral load at country 
level is conirmed. The lexibility, offered by such open sys-
tems in the choice of complementary equipments or reagents 
for nucleic acid extraction and ampliication, allows reducing 
signiicantly the cost of this analysis compared to the tests 
commercialized today. Such open systems could be also use-
ful in the future for the quantiication of other viruses such as 
hepatitis B and C, particularly endemic in the country. 
The success of this initiative is also due to the establish-
ment of periodic national HIV workshops. The dynamic in-
duced by these meetings allows all partners and stakeholders 
in the ight against HIV/AIDS to be kept informed of the use 
of this viral marker across the country, to be aware of prob-
lems and to conduct rapid corrective actions. There is no 
doubt that the active participation of clinicians, laboratories, 
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members of associations representative of people leaving 
with HIV and the involvement of national and international 
experts, contribute to improving the medical care and treat-
ment of patients in Laos PDR. Preliminary results show 84% 
of virological success. This good result is close to that esti-
mated in other limited resources countries, for example, in 
neighbouring Cambodia (Janssens et al, 2007; Ségéral et al, 
2011; Ferradini et al, 2007). This should encourage health 
authorities to intensify their efforts in the use of viral load. 
These results highlight the importance of continually enhanc-
ing the adherence of patients to their treatments, to reduce the 
emergence of resistant viruses. 
HIV RNA/DNA viral load and antiretroviral resistance 
testing are now operational at the CICML. Health authorities 
may rely on that expertise to strengthen the ight against HIV/
AIDS to contain HIV spreading across the country. Indeed, 
only 3,000 on the estimated 8,000 individuals living with 
HIV in need of ART are currently registered and followed up 
in treatment centres. Another challenge will be to improve 
the prevention of mother to child transmission of HIV and to 
prevent the spread of HIV in populations at risk. 
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